Skip to main content

Table 1 Planning objectives for dose-escalated prostate SBRT

From: Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking

 

Dose objective

Expected (4 fractions)

Expected (5 fractions)

Priority

Rectum

Dmax (0.035 cc)

38 Gy (100% prescribed dose)

42 Gy (105% prescribed dose)

1

D5%

 ≤ 33 Gy

 ≤ 40 Gy

2

D10%

 ≤ 29 Gy

 ≤ 36 Gy

2

D20%

 ≤ 26.5 Gy

 ≤ 32 Gy

2

D50%

 ≤ 16.7 Gy

 ≤ 20 Gy

2

Rectal mucosa

Dmax (0.035 cc)

28.5 (75% prescribed dose)

–

1

Bladder

Dmax (0.035 cc)

45.6 Gy (120% prescribed dose)

44 Gy (110% prescribed dose)

1

D10%

 ≤ 41.8 Gy (110% prescribed dose)

 ≤ 38 Gy (95% prescribed dose)

1

D40%

 ≤ 16.6 Gy

 ≤ 20 Gy

2

PRV Urethra

Dmax (0.035 cc)

45.6 Gy (120% prescribed dose)

48 Gy (120% prescribed dose)

1

D10%

 ≤ 41.8 Gy (110% prescribed dose)

 ≤ 44 Gy (110% prescribed dose)

1

Penile bulb

Dmax (0.035 cc)

38 Gy (100% prescribed dose)

40 Gy (100% prescribed dose)

3